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BACKGROUND: Tracheo-esophageal ﬁstula (TEF) with/or without esophageal atresia (EA) is a common con-
genital malformation that is often accompanied by other anomalies. The causes of this condition are thought
to be heterogeneous but are overall not well understood. CASE REPORT: We identiﬁed a patient with a TEF/
EA, as well as cardiac and genitourinary anomalies, who was found to have a 0.7 Mb de novo deletion of
chromosome 20q13.33. One gene within the deleted interval, GTPBP5, is of particular interest as a candidate
gene. CONCLUSIONS: GTPBP5 bears further study as a cause of TEF/EA accompanied by other malforma-
tions. Birth Defects Research (Part A) 91:862865, 2011.  2011 Wiley-Liss, Inc.
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INTRODUCTION
Tracheo-esophageal ﬁstula (TEF) with or without
esophageal atresia (EA) is a relatively common malfor-
mation, occurring in approximately 1 in 3500 births
(Torfs et al., 1995). Approximately half of patients have
accompanying malformations, such as occur in Feingold
syndrome, anophthalmia-esophageal-genital syndrome,
CHARGE syndrome, vertebral anomalies, anal atresia,
cardiovascular anomalies, tracheoesophageal ﬁstula,
esophageal atresia, renal or radial anomalies, or limb
defects (VACTERL) association, and other, less well-
characterized conditions involving multiple malforma-
tions. Among these accompanying congenital anomalies,
cardiac defects are especially common (reviewed in
ShawSmith, 2006; de Jong et al., 2010).
Although the causes of some of the syndromic condi-
tions that may include TEF/EA have been deﬁned, the
etiologies of others are less well-understood. TEF/EA is
viewed as a complex, heterogeneous disorder resulting
from multiple interacting genetic and environmental
factors. Many questions remain regarding the genetic
contributions to isolated TEF/EA, although there are
hints from biologic models implicating key pathways
including the Sonic hedgehog signaling network
(reviewed in de Jong et al., 2010).
Speciﬁc chromosomal anomalies, such as trisomy 13,
18, and 21 have long been known to be associated
with TEF/EA, as well as with other congenital malforma-
tions (Torfs et al., 1995). Chromosomal rearrangements
visible on routine karyotype, as well as submicroscopic
pathogenic copy number variations (CNVs) of numerous
chromosomal loci, have also been implicated as causing
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reported in multiple affected individuals, while others
have been described in only a single patient (Felix et al.,
2007). Overall, these results support a heterogeneous
model of causation.
We performed high-density microarrays on a cohort of
20 patients ascertained through our study on VACTERL
association, with the hypothesis that this testing modality
would reveal potentially explanatory genomic imbalances
in some patients. One patient had a submicroscopic de
novo deletion of chromosome 20q13.33, part of which
did not overlap known regions of copy-number variation.
Of note, while this patient met inclusion criteria for our
study, most clinicians and researchers would not judge
him as having ‘‘classic’’ VACTERL association. However,
the deletion found in this patient suggests GTPBP5 as a
key gene contributing to the patient’s presentation.
CASE REPORT
Patient
The patient was a 6-month-old white infant with a his-
tory of a TEF and EA, cardiac anomalies consisting of
two ventricular septal defects, hypospadias, and a large
unilateral hydrocele, as well as a large left cystic
hygroma that self-resolved during infancy. He and his
parents participated in our Institutional Review Board-
approved National Human Genome Research Protocol on
VACTERL association, with appropriate consent obtained
from all participants. (Most clinicians and researchers
would not consider this patient to have classic VACTERL
association, as he did not have at least three component
features, but he met the criteria for inclusion in our study
based on the presence of two component features and an
additional congenital malformation (Solomon et al.,
2010a).
On physical examination, weight and height were
slightly less than the third centile for age; head circum-
ference was approximately 25th centile for age. He was
not dysmorphic, and developmental milestones were
appropriate at the time of evaluation, although at follow-
up approximately 1 year later, he was reported to be
receiving treatment for speech delay. He was his parents’
only child; family history was noncontributory for any
similar conditions. Traditional karyotype performed
before research participation showed a normal male chro-
mosome complement.
Microarray Analysis
We extracted genomic DNA from peripheral blood sam-
ples using a QIAamp DNA Blood Maxi kit (Qiagen, Ger-
mantown, MD) per protocol. Microarray analysis was per-
formed using the Illumina Omni1-Quad single-nucleotide
polymorphism (SNP) array, which contains over 1 million
SNP loci, with 300 ng of DNA (4 llo f7 5n g / llD N A )p e r
the Illumina ‘‘inﬁnium assay’’ protocol (Gunderson et al.,
2005). We collected data using the BeadArray scanner, and
visualized data with the GenomeStudio (v2009.2, www.Il-
lumina.com) genotyping module, using human genome
build 36.1 (NCBI36/hg18) for analysis. The call rates for all
the DNA samples were >99%. CNVs were detected using
PennCNV software ﬁltered to annotate regions with at
least three contiguous SNPs with the same abnormality
(Wang et al., 2007). Detected regions of genomic imbalan-
ces were compared to known CNVs in control populations
with the Database of Genomic Variants (Zhang et al.,
2006). Potentially pathogenic variants were further com-
pared to 745 total individuals, none of whom had similar
Figure 1. De novo 0.7 Mb deletion of chromosome 20q13.33 in the patient described here, ascertained with Illumina Omni1-Quad high-
density single-nucleotide polymorphism (SNP) microarray platform, and visualized using GenomeStudio (v2009.2, www.Illumina.com)
genotyping module. The deletion is indicated by the arrow; the corresponding chromosomal region is outlined in the ideogram below.
The proband’s microarray is uppermost; parental arrays of the same region are shown below the proband’s. [Color ﬁgure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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(192: Illumina OmniExpress; 206: Illumina 1M-Duo; 347:
Illumina Omni1-Quad).
The microarray revealed an approximately 0.7 Mb de
novo (with parentage conﬁrmed by microarray analysis) in-
terstitial deletion on chromosome 20q13.33:
arr20q13.33(59,671,82160,329,092)x1 dn (Fig. 1). This
deletion was conﬁrmed by oligonucleotide microarray (tar-
geted 60K oligonucleotide microarray performed at Gen-
eDx, Gaithersburg, MD), as well as quantitative PCR of one
of the genes (TAF4) in the deleted interval. Genes in the
deleted interval include: CDH4, MIR1257, TAF4, LSM14B,
PSMA7, SS18L1, GTPBP5, HRH3, OSBPL2, LAMA5, and
ADRM1. There are small copy number variations in normal
controls within this interval on chromosome 20, but none
overlapping all of these genes or nearly as large as this dele-
tion. In particular, deletions of GTPBP5 have not been
reported in control populations (Zhang et al., 2006). CNVs
involving LSM14B have also not been reported, but very lit-
tle is reported regarding the role of this gene. This deletion
was additionally not found in 745 individuals who under-
went high-density microarray analysis for reasons other
than similar congenital malformations.
DISCUSSION
Many different genomic imbalances have been
reported in patients with TEF/EA (Felix et al., 2007). The
deletion found in this patient is especially interesting as
it suggests only two speciﬁc genes as being contributory:
among the genes in the patient’s deleted region, GTPBP5
and LSM14B are the only ones that have not been
reported as copy number variations in normal controls.
Relatively little is known about the function of these
genes, but interestingly, disturbances of the GTPBP5’s
function result in abnormal mitochondria (Hirano et al.,
2006). Mitochondrial dysfunction is a well-documented
link to congenital malformations such as those seen in
VACTERL association, which this patient has features of,
even if he were not deemed to meet strict diagnostic cri-
teria (Damian et al., 1996; von KleistRetzow et al., 2003;
ThauvinRobinet et al., 2006; Solomon et al., 2011).
From a developmental standpoint, LAMA5 is another
interesting candidate gene, although with some strong
caveats. LAMA5-null mice die in utero with multiple
malformations; hypomorphic animals display anomalies
such as renal and pulmonary malformations (Nguyen
et al., 2002; Shannon et al., 2006). Further, LAMA5
interacts with Sonic Hedgehog, a pathway frequently
implicated in conditions that include TEF/EA such as
VACTERL association (Kim et al., 2001; Gao et al., 2008).
However, the mouse models do not correlate well with
the speciﬁc malformations seen in this particular patient,
and further, deletions of this gene have been reported in
normal controls (Jakobsson et al., 2008).
The deleted region overlaps that reported in another
patient, although this previously reported patient had a
much larger deletion, making further comparisons quite
speculative. This patient, like the one described here, was
nondysmorphic; her phenotype interestingly included
cardiac anomalies, as well as hydronephrosis (Traylor
et al., 2010).
The fact that the deletion is de novo offers some evi-
dence of possible pathogenicity. One additional possibil-
ity that cannot be ignored involves a recessive model in
which the patient had, for example, a deletion of one al-
lele and a point mutation in the other. However, further
studies would be required to investigate this possibility.
Finally, it must be emphasized that while the patient
was ascertained through a study focusing on VACTERL
association, he had only two strict component features of
VACTERL association, and thus should not be consid-
ered to have this diagnosis (although he also had genito-
urinary anomalies, which are frequent in patients with
VACTERL association; Solomon et al., 2010b). Neverthe-
less, we hope that these results may be extrapolated to
inspire further research on the causes of TEF/EA
through molecular studies of GTPBP5.
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